Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2011 | 09-2011 | 06-2011 | 03-2011 | 12-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,390 | 7,940 | 7,980 | 6,940 | 5,890 |
| Receivables | 0 | 0 | 0 | 0 | 230 |
| Other current assets | 6 | 50 | 70 | 80 | 0 |
| TOTAL | $6,500 | $7,990 | $8,050 | $7,020 | $6,190 |
| Non-Current Assets | |||||
| PPE Net | 6 | N/A | N/A | N/A | 7 |
| Intangibles | 36 | 0 | 0 | 0 | 39 |
| Other Non-Current Assets | 48 | 90 | 90 | 80 | 34 |
| TOTAL | $90 | $90 | $90 | $80 | $80 |
| Total Assets | $6,610 | $8,100 | $8,160 | $7,120 | $6,300 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 380 | 190 | 120 | 180 | 120 |
| Accrued Expenses | 1,550 | 410 | 450 | 180 | 580 |
| Other current liabilities | 280 | 200 | 200 | 490 | 1,060 |
| TOTAL | $2,210 | $810 | $780 | $850 | $1,770 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 200 | N/A | N/A | N/A | 200 |
| Other Non-Current Liabilities | 0 | 0 | 3 | 7 | 10 |
| TOTAL | $N/A | $N/A | $3 | $7 | $10 |
| Total Liabilities | $2,210 | $810 | $780 | $860 | $1,780 |
| Shareholders' Equity | |||||
| Common Shares | 10 | 70 | 70 | 60 | 60 |
| Retained earnings | -69,130 | -65,410 | -63,080 | -59,140 | -56,420 |
| Other shareholders' equity | 7,150 | 7,090 | 7,100 | 7,040 | 6,850 |
| TOTAL | $4,390 | $7,280 | $7,370 | $6,250 | $4,510 |
| Total Liabilities And Equity | $6,600 | $8,090 | $8,150 | $7,110 | $6,290 |